Loading
Dormant cancer cells hide in bone marrow. A lab-built model of that hiding place would let us watch them sleep and wake, and test drugs on them.
Microfluidic and organ-on-chip systems can now sustain human haematopoietic niches with mesenchymal stroma, osteoblasts and vasculature under flow. Adding patient-derived tumour cells creates a human dormancy model with live-cell imaging, in which awakening triggers such as inflammation, chemotherapy or niche disruption can be dialled in and quantified.
Shares Functional (ex vivo) drug testing, Single-cell & spatial profiling, Patient-derived organoids, Lab models that fail to predict what happens in patients.
Shares Functional (ex vivo) drug testing, Patient-derived organoids, Lab models that fail to predict what happens in patients, Dormant cells and minimal residual disease.
Shares Functional (ex vivo) drug testing, Patient-derived organoids.
Shares Functional (ex vivo) drug testing, Patient-derived organoids.
Shares Functional (ex vivo) drug testing, Patient-derived organoids.
Shares Functional (ex vivo) drug testing, Patient-derived organoids.
Shares Functional (ex vivo) drug testing, Single-cell & spatial profiling.
Shares Functional (ex vivo) drug testing, Patient-derived organoids.